Ezivac%2525252520enema

# Ezivac Enema ## Overview Ezivac (Sodium Phosphates Enema) is a hypertonic osmotic laxative. It works by increasing fluid retention in the bowel and stimulating peristalsis via local irritation of the rectal mucosa. ## Primary Indications * Relief of occasional constipation. * Bowel evacuation prior to rectal examinations or surgery. ## Adult Dosing * **Standard dose:** 118 mL (one ready-to-use squeeze bottle). * **Administration:** Administer rectally once daily or as directed by a physician. * **Maximum:** Do not exceed one dose in a 24-hour period. ## Pediatric Dosing * **Children 12 years and older:** Same as adult dose (118 mL). * **Children 2 to under 12 years:** Consult a pediatrician regarding pediatric-specific formulations; typically 59 mL (half of an adult bottle). * **Children under 2 years:** Contraindicated. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Risk of hyperphosphatemia, hypocalcemia, and hypernatremia. * **Hepatic Impairment:** No specific adjustment, but monitor for electrolyte disturbances. ## Contraindications * Hypersensitivity to any component. * Congestive heart failure. * Clinically significant renal impairment or end-stage renal disease. * Suspected bowel obstruction, megacolon, or inflammatory bowel disease (ulcerative colitis, Crohn’s). * Symptomatic hemorrhoids or rectal bleeding. ## Adverse Effects * **Common:** Rectal irritation, abdominal pain, nausea. * **Serious:** Severe electrolyte disturbances (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), dehydration, metabolic acidosis, and cardiac arrhythmias secondary to electrolyte shifts. ## Key Drug Interactions * **Diuretics (loop/thiazide) and ACE inhibitors/ARBs:** Increased risk of renal impairment and electrolyte instability. * **Calcium Channel Blockers:** Potential for increased risk of hypocalcemia. * **Other laxatives:** Increased risk of dehydration and electrolyte depletion. ## Monitoring * Monitor serum electrolytes (sodium, potassium, phosphorus, calcium) in patients at risk for imbalances. * Monitor renal function (BUN/Cr). * Assess for clinical signs of dehydration (dizziness, thirst, hypotension). ## Clinical Pearls * **Positioning:** Instruct patient to lie on the left side with knees bent (Sims' position) during insertion to facilitate flow with gravity. * **Safety:** Do not force insertion; if resistance is met, stop immediately to avoid rectal perforation. * **Hydration:** Strongly encourage adequate oral fluid intake before and after administration to mitigate dehydration. * **Duration:** Discontinue use if symptoms of constipation persist beyond 7 days or if no bowel movement occurs within 30 minutes of administration. *** *Disclaimer: This information is for educational purposes only. Clinical practice guidelines and local protocols vary. Verify all dosing, compatibility, and contraindications against current institutional guidelines and the product package insert before prescribing or administering medication.*